EE200100085A - Asendatud 1,8-naftüridiin-4(1H)-oonid kui fosfodiesteraas 4 inhibiitorid - Google Patents

Asendatud 1,8-naftüridiin-4(1H)-oonid kui fosfodiesteraas 4 inhibiitorid

Info

Publication number
EE200100085A
EE200100085A EEP200100085A EEP200100085A EE200100085A EE 200100085 A EE200100085 A EE 200100085A EE P200100085 A EEP200100085 A EE P200100085A EE P200100085 A EEP200100085 A EE P200100085A EE 200100085 A EE200100085 A EE 200100085A
Authority
EE
Estonia
Prior art keywords
naphthyridin
phosphodiesterase
inhibitors
ones
substituted
Prior art date
Application number
EEP200100085A
Other languages
English (en)
Estonian (et)
Inventor
Fox Kleinman Edward
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200100085A publication Critical patent/EE200100085A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
EEP200100085A 1998-08-11 1999-08-05 Asendatud 1,8-naftüridiin-4(1H)-oonid kui fosfodiesteraas 4 inhibiitorid EE200100085A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9617698P 1998-08-11 1998-08-11
PCT/IB1999/001390 WO2000009504A1 (fr) 1998-08-11 1999-08-05 1,8-naphtyridin-4(h)-ones substituees comme inhibiteurs de la phosphodiesterase 4

Publications (1)

Publication Number Publication Date
EE200100085A true EE200100085A (et) 2002-08-15

Family

ID=22256080

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100085A EE200100085A (et) 1998-08-11 1999-08-05 Asendatud 1,8-naftüridiin-4(1H)-oonid kui fosfodiesteraas 4 inhibiitorid

Country Status (44)

Country Link
US (1) US6174895B1 (fr)
EP (1) EP1104420B1 (fr)
JP (1) JP2002522541A (fr)
KR (1) KR20010072368A (fr)
CN (1) CN1312810A (fr)
AP (1) AP2001002068A0 (fr)
AR (1) AR015557A1 (fr)
AT (1) ATE229955T1 (fr)
AU (1) AU4924999A (fr)
BG (1) BG105321A (fr)
BR (1) BR9912902A (fr)
CA (1) CA2340180A1 (fr)
CO (1) CO5130004A1 (fr)
CZ (1) CZ2001485A3 (fr)
DE (1) DE69904602T2 (fr)
DK (1) DK1104420T3 (fr)
DZ (1) DZ2866A1 (fr)
EA (1) EA200100124A1 (fr)
EE (1) EE200100085A (fr)
ES (1) ES2188194T3 (fr)
GE (1) GEP20033029B (fr)
GT (1) GT199900128A (fr)
HK (1) HK1038917A1 (fr)
HN (1) HN1999000130A (fr)
HR (1) HRP20010107A2 (fr)
HU (1) HUP0103466A3 (fr)
ID (1) ID27843A (fr)
IL (1) IL140868A0 (fr)
IS (1) IS5815A (fr)
MA (1) MA26669A1 (fr)
NO (1) NO20010684L (fr)
NZ (1) NZ509297A (fr)
OA (1) OA11591A (fr)
PA (1) PA8480001A1 (fr)
PE (1) PE20000950A1 (fr)
PL (1) PL346005A1 (fr)
PT (1) PT1104420E (fr)
SK (1) SK1822001A3 (fr)
SV (1) SV1999000120A (fr)
TN (1) TNSN99155A1 (fr)
TR (1) TR200100433T2 (fr)
TW (1) TW542835B (fr)
WO (1) WO2000009504A1 (fr)
ZA (1) ZA200101040B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815951B2 (en) 1996-08-13 2014-08-26 The Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of inflammation
EP1343528A2 (fr) * 2000-11-02 2003-09-17 Research Foundation of City University of New York Procedes de stimulation de la regeneration et de la reparation du systeme nerveux par inhibition de la phosphodiesterase de type 4
WO2002088079A2 (fr) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Inhibiteurs doubles de pde 7 et pde 4
JO2311B1 (en) * 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
US7323460B2 (en) 2002-03-15 2008-01-29 Merck & Co., Inc. N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as HIV integrase inhibitors
KR100454750B1 (ko) * 2002-06-20 2004-11-03 삼성에스디아이 주식회사 유기 전계 발광 소자용 청색 발광 화합물 및 이를 사용한유기 전계 발광 소자
US20060079540A1 (en) * 2002-11-27 2006-04-13 Altana Pharma Ag Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE10349497A1 (de) * 2003-10-23 2005-05-25 Bayer Cropscience Ag N-substituierte Pyrazolylcarboxanilide
JP2007517828A (ja) * 2004-01-17 2007-07-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 気道の疾患を治療するための置換プテリジンの使用
DE102004002557A1 (de) * 2004-01-17 2005-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
EP1632493A1 (fr) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dérivés de dihydropteridine, méthodes de préparation et utilisation en tant que médicament
EP1630163A1 (fr) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, procédés de préparation et leur utilisation en tant que médicaments
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
EP1915155A1 (fr) * 2005-08-03 2008-04-30 Boehringer Ingelheim International GmbH Dihydropteridinones utilisees pour le traitement de maladies respiratoires
US7439358B2 (en) * 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
WO2009019205A1 (fr) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Forme cristalline d'un dérivé de dihydroptéridione
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
ES2773272T3 (es) * 2012-08-08 2020-07-10 Merck Patent Gmbh Derivados de (aza-)isoquinolinona
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
WO2015011236A1 (fr) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Traitement du syndrome myélodysplasique
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU165405B (fr) * 1972-06-29 1974-08-28
US3856800A (en) * 1973-02-26 1974-12-24 Sterling Drug Inc Process of preparing 1,4-dihydro-4-oxo-7-q-3-unsubstituted-1,8-naphthyridines from cyclic alkylidenyl n-(6-q-2-pyridyl) aminomethylenemalonates
US3882132A (en) * 1973-03-08 1975-05-06 Sterling Drug Inc Preparation of 1-alkyl-1,4-dihydro-7-substituted-4-oxo-1,8-naphthyridine-3-carboxylic acids via the 3-aminomethyl analogs
US5817670A (en) * 1994-08-29 1998-10-06 Yamanouchi Pharmaceutical Co., Ltd. Naphthyridine derivatives and pharmaceutical compositions thereof
JP4323574B2 (ja) * 1995-12-13 2009-09-02 大日本住友製薬株式会社 抗腫瘍剤

Also Published As

Publication number Publication date
ID27843A (id) 2001-04-26
NZ509297A (en) 2003-11-28
GEP20033029B (en) 2003-07-25
PL346005A1 (en) 2002-01-14
IL140868A0 (en) 2002-02-10
HN1999000130A (es) 2000-11-22
CA2340180A1 (fr) 2000-02-24
EA200100124A1 (ru) 2001-10-22
ES2188194T3 (es) 2003-06-16
PT1104420E (pt) 2003-03-31
OA11591A (en) 2004-07-30
BR9912902A (pt) 2001-05-08
CZ2001485A3 (cs) 2002-05-15
PE20000950A1 (es) 2000-09-27
MA26669A1 (fr) 2004-12-20
TW542835B (en) 2003-07-21
IS5815A (is) 2001-01-16
ATE229955T1 (de) 2003-01-15
DE69904602D1 (en) 2003-01-30
HK1038917A1 (zh) 2002-04-04
HUP0103466A3 (en) 2002-11-28
AU4924999A (en) 2000-03-06
PA8480001A1 (es) 2000-09-29
DE69904602T2 (de) 2003-04-30
DK1104420T3 (da) 2003-01-13
CO5130004A1 (es) 2002-02-27
EP1104420B1 (fr) 2002-12-18
HRP20010107A2 (en) 2002-02-28
TR200100433T2 (tr) 2001-07-23
HUP0103466A2 (hu) 2002-02-28
DZ2866A1 (fr) 2003-12-01
JP2002522541A (ja) 2002-07-23
BG105321A (en) 2001-12-29
SK1822001A3 (en) 2002-08-06
GT199900128A (es) 2001-01-30
EP1104420A1 (fr) 2001-06-06
NO20010684D0 (no) 2001-02-09
WO2000009504A1 (fr) 2000-02-24
ZA200101040B (en) 2003-01-07
CN1312810A (zh) 2001-09-12
NO20010684L (no) 2001-04-09
AP2001002068A0 (en) 2001-03-31
AR015557A1 (es) 2001-05-02
KR20010072368A (ko) 2001-07-31
TNSN99155A1 (fr) 2005-11-10
SV1999000120A (es) 2000-09-05
US6174895B1 (en) 2001-01-16

Similar Documents

Publication Publication Date Title
EE200100085A (et) Asendatud 1,8-naftüridiin-4(1H)-oonid kui fosfodiesteraas 4 inhibiitorid
EE200200140A (et) Pteridinoonid kui kinaasi inhibiitorid
PT1049695E (pt) Imidazotriazinonas 2-fenil substituidas enquanto inibidores de fosfodiesterase
EE200100166A (et) 4-karboksüamino-2-asendatud 1, 2, 3, 4-tetrahüdrokinoliinid kui CETP inhibiitorid
EE05362B1 (et) Aniliini derivaadid, mis on kasulikud kui fosfodiesteraas 4 inhibiitorid
AU2002253794A1 (en) Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
IL141445A0 (en) Benzazine derivatives as phosphodiesterase 4 inhibitors
EE200200192A (et) 5-(2-asendatud-5-heterotsüklüülsulfonüülpürid-3-üül)dihüdropürasolo[4,3-d]pürimidii n-7-oonid kui fosfodiesteraasi inhibiitorid
EE200000411A (et) Bitsüklilised heteroaromaatsed ühendid kui valgu türosiini kinaasi inhibiitorid
EE200100368A (et) w-karboksüarüülasendatud difenüülkarbamiidid kui raf-kinaasi inhibiitorid
AU6117801A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
HUP0202034A2 (en) Heterocyclic substituted aminoazacycles useful as central nervous system agents
DE60205921D1 (de) SUBSTITUIERTE 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDOç1,2-A!PYRIMIDIN-4-ON- UND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO-ç1,2-A!PYRIMIDIN-5(1H)ONDERIVATE
EE200100039A (et) Ftalasiinderivaadid kui fosfodiesteraas-4 inhibiitorid
ATE387448T1 (de) 4,5-pyrazinoxindole als proteinkinasehemmer
ID27845A (id) Turunan tetrahidrokuilina sebagai antagonis glisilina
GB9706652D0 (en) Inhibitors of FPT as anti-inflammatories
DK1010699T3 (da) 5-substituerede 3-oxadiazolyl-1,6-naphthyridin-2(1H)-on-derivater
SI1296981T1 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
FI980377A0 (fi) Foerfarande foer saogning av en stock med beaktande av radial- och aorsringsriktningarna i tvaersnittet